The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Feb-25
Pending
$1.1 billion
Target:
PRISM Vision Group
Acquiror:
McKesson Corporation
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
28-Jan-25
$219 million
Target:
The Container Store, Inc.
Advised the Ad Hoc Group of Term Loan Lender to The Container Store on its Pre Packaged Chapter 11 Restructuring
27-Nov-24
$618 million
Target:
Empire Today
Advised Empire Today, the largest and only national DTC provider of replacement hard surface flooring and carpet in the U.S., on its liability management transaction
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
20-Jun-24
Pending
$1.8 billion
Target:
CP Kelco
Acquiror:
Tate & Lyle
Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
01-May-24
Undisclosed
Target:
Functional Formularies
Acquiror:
Danone
Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital
16-Nov-23
~$400 million
Target:
Sonoma-Cutrer Vineyards (Brown-Forman)
Acquiror:
The Duckhorn Portfolio
Advised Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
16-Feb-23
Pending
$220 million
Target:
Flavor Specialty Ingredients division of IFF
Acquiror:
Exponent Private Equity
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
03-Nov-22
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
MVolution Partners
Advised Pixelligent Technologies, a leading manufacturer of nanocrystal material used in consumer electronic devices, on its growth capital raise
25-Oct-22
Pending
Undisclosed
Target:
Acreage Holdings
Acquiror:
Canopy Growth Corporation
Advising Canopy Growth, a leading diversified cannabis company, on the re-organization and consolidation of its U.S. cannabis assets under a new holding company, Canopy USA, and on related investments and debt repurchase transactions
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
08-Aug-22
Pending
$3.0 billion
Target:
InSinkErator (Emerson Electric)
Acquiror:
Whirlpool Corporation
Advised Whirlpool Corporation on its announced acquisition of InSinkErator, the world’s largest manufacturer of food waste disposers and instant hot water dispensers for home and commercial use from Emerson Electric for cash consideration of $3.0 billion
30-Jun-22
Undisclosed
Target:
Sands Family
Acquiror:
Constellation Brands, Inc
Advised the Sands Family in connection with the elimination of Constellation Brands' Class B common stock, which included the conversion of each share of Class B common stock into the right to receive one share of Class A common stock plus $64.64 in cash consideration
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
01-Feb-22
Undisclosed
Target:
Alteon Health
Acquiror:
U.S. Acute Care Solutions
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
28-Jan-22
Undisclosed
Target:
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Acquiror:
Laboratoires Théa SAS
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
08-Dec-21
$240 million
Target:
Alert 360
Acquiror:
My Alarm Center
Advising My Alarm Center, a nationwide provider of security and smart home monitoring services, on the acquisition of Alert 360, a leading competitor in the alarm monitoring industry